Cohen, C. J., Molina, J. M., Cahn, P., Clotet, B., Fourie, J., Grinsztejn, B., . . . Boven, K. (2018). Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials.
Chicago Style CitationCohen, Calvin J., et al. Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz At 48 Weeks in Treatment-naive HIV-1-infected Patients: Pooled Results From the Phase 3 Double-blind Randomized ECHO and THRIVE Trials. 2018.
MLA引文Cohen, Calvin J., et al. Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz At 48 Weeks in Treatment-naive HIV-1-infected Patients: Pooled Results From the Phase 3 Double-blind Randomized ECHO and THRIVE Trials. 2018.